TIMP-1 in patients with cirrhosis: Relation to liver dysfunction, portal hypertension, and hemodynamic changes

Scandinavian Journal of Gastroenterology

Volumn 49, Issue 9, 2014, Pages 1103-1110

  Busk, Troels M ^a   Bendtsen, Flemming ^a,b   Nielsen, Hans J ^a,b   Jensen, Vibeke ^b   Brünner, Nils ^b   Moller, Soren ^a,b  

^a HVIDOVRE HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Biomarker; Cirrhosis; Portal hypertension; TIMP 1

Indexed keywords

INDOCYANINE GREEN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; BIOLOGICAL MARKER; TIMP1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; ASCITES; CHILD TURCOTTE PUGH SCORE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; DRUG CLEARANCE; FEMALE; HEMODYNAMIC PARAMETERS; HUMAN; INDOCYANINE GREEN ANGIOGRAPHY; LIVER BLOOD VESSEL; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER VEIN; LIVER VEIN CATHETERIZATION; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; PORTAL HYPERTENSION; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SYSTEMIC VASCULAR RESISTANCE; VEIN CATHETERIZATION; ARTERIAL PRESSURE; BLOOD; COMPLICATION; HEPATIC ARTERY; HYPERTENSION, PORTAL; MIDDLE AGED; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX; VASCULAR RESISTANCE;

ADULT; AGED; ARTERIAL PRESSURE; BIOLOGICAL MARKERS; FEMALE; HEPATIC ARTERY; HEPATIC VEINS; HUMANS; HYPERTENSION, PORTAL; LIVER CIRRHOSIS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; ROC CURVE; SEVERITY OF ILLNESS INDEX; TISSUE INHIBITOR OF METALLOPROTEINASE-1; VASCULAR RESISTANCE;

EID: 84906314164     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2014.934910     Document Type: Article

References (30)

1. Groszmann RJ, Garcia-Tsao G, Bosch J, Grace ND, Burroughs AK, Planas R, et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med 2005;353:2254-61
2. de Franchis R. Revising consensus in portal hypertension: Report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2010;53:762-8
3. Piccinino F, Sagnelli E, Pasquale G, Giusti G. Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies. J Hepatol 1986;2:165-73
4. Hobolth L, Bendtsen F, Møller S. Indications for portal pressure measurement in chronic liver disease. Scand J Gastroenterol 2012;8-9:887-92
5. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: A prospective study. Lancet 2001;357:1069-75
6. Rosenberg WM, Voelker M, Thiel R, Becka M, Burt A, Schuppan D, et al. Serum markers detect the presence of liver fibrosis: A cohort study. Gastroenterology 2004;127:1704-13
7. Cales P, Oberti F, Michalak S, Hubert-Fouchard I, Rousselet MC, Konate A, et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 2005;42:1373-81
8. Koda M, Matunaga Y, Kawakami M, Kishimoto Y, Suou T, Murawaki Y. FibroIndex, a practical index for predicting significant fibrosis in patients with chronic hepatitis C. Hepatology 2007;45:297-306
9. Castera L, Pinzani M, Bosch J. Non invasive evaluation of portal hypertension using transient elastography. J Hepatol 2012;56:696-703
10. Yoshiji H, Kuriyama S, Miyamoto Y, Thorgeirsson UP, Gomez DE, Kawata M, et al. Tissue inhibitor of metalloproteinases-1 promotes liver fibrosis development in a transgenic mouse model. Hepatology 2000;32:1248-54
11. Benyon RC, Iredale JP, Goddard S, Winwood PJ, Arthur MJ. Expression of tissue inhibitor of metalloproteinases 1 and 2 is increased in fibrotic human liver. Gastroenterology 1996;110:821-31
12. Ramachandran P, Iredale JP. Reversibility of liver fibrosis. Ann Hepatol 2009;8:283-91
13. Iredale JP, Thompson A, Henderson NC. Extracellular matrix degradation in liver fibrosis: Biochemistry and regulation. Biochim Biophys Acta 2013;1832:876-83
14. Gluud C. Serum testosterone concentrations in men with alcoholic cirrhosis: Background for variation. Metabolism 1987;36:373-8
15. Møller S, Bendtsen F, Henriksen JH. Effect of volume expansion on systemic hemodynamics and central and arterial blood volume in cirrhosis. Gastroenterology 1995;109:1917-25
16. Møller S, Hillingsø J, Christensen E, Henriksen JH. Arterial hypoxaemia in cirrhosis: Fact or fiction?. Gut 1998;42:868-74
17. Holten-AndersenMN,Murphy G, Nielsen HJ, Pedersen AN, Christensen IJ, Høyer-Hansen G, et al. Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer. Br J Cancer 1999;80:495-503
18. Gines P, Cardenas A, Arroyo V, Rodes J. Management of cirrhosis and ascites. N Engl J Med 2004;350:1646-54
19. Lichtinghagen R, Pietsch D, Bantel H, Manns MP, Brand K, Bahr MJ. The Enhanced Liver Fibrosis (ELF) score: Normal values, influence factors and proposed cut-off values. J Hepatol 2013;59:236-42
20. Ponomarenko Y, Leo MA, Kroll W, Lieber CS. Effects of alcohol consumption on eight circulating markers of liver fibrosis. Alcohol Alcohol 2002;37:252-5
21. Thabut D, Imbert-Bismut F, Cazals-Hatem D, Messous D, Muntenau M, Valla DC, et al. Relationship between the Fibrotest and portal hypertension in patients with liver disease. Aliment Pharmacol Ther 2007;26: 359-68
22. Nøjgaard C, Johansen JS, Christensen E, Skovgaard LT, Price PA, Becker U. Serum levels of YKL-40 and PIIINP as prognostic markers in patients with alcoholic liver disease. J Hepatol 2003;39:179-86
23. Grønbæk H, Sandahl TD, Mortensen C, Vilstrup H, Møller HJ, Møller S. Soluble CD163, a marker of Kupffer cell activation, is related to portal hypertension in patients with liver cirrhosis. Aliment Pharmacol Ther 2012;36: 173-80
24. La Mura V, Reverter JC, Flores-Arroyo A, Raffa S, Reverter E, Seijo S, et al. Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension. Gut 2011;60:1133-8
25. Berzigotti A, Seijo S, Arena U, Abraldes JG, Vizzutti F, Garcia-Pagan JC, et al. Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis. Gastroenterology 2013;144:102-11
26. Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 2007;46:922-38
27. Fontana RJ, Goodman ZD, Dienstag JL, Bonkovsky HL, Naishadham D, Sterling RK, et al. Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology 2008;47:789-98
28. Fontana RJ, Dienstag JL, Bonkovsky HL, Sterling RK, Naishadham D, Goodman ZD, et al. Serum fibrosis markers are associated with liver disease progression in nonresponder patients with chronic hepatitis C. Gut 2010;59: 1401-9
29. Frederiksen C, Lykke J, Christensen IJ, Brünner N, Nielsen HJ. Tissue inhibitor of metalloproteinase-1 levels in plasma from tumour arteries and veins of patients with rectal cancer. Scand J Clin Lab Invest 2007;67:545-52
30. Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Nakatani T, et al. Tissue inhibitor of metalloproteinases-1 attenuates spontaneous liver fibrosis resolution in the transgenic mouse. Hepatology 2002;36:850-60.